We are live on !
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter Est. Return
+32.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$343M
AUM Growth
+$158M
(+86%)
Cap. Flow
+$103M
Cap. Flow % of AUM
Cap. Flow %
29.91%
Top 10 Holdings %
Top 10 Hldgs %
65.57%
Holding
72
New
18
Increased
24
Reduced
6
Closed
20
Avg Time Held
Equity + Options
0.6
years
Top 10 Avg Time Held
Equity + Options
0.6
years
Top 20 Avg Time Held
Equity + Options
0.6
years
Avg Time Held Equity only
0.7
years
Top 10 Avg Time Held Equity only
0.6
years
Top 20 Avg Time Held Equity only
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NUVA
NuVasive, Inc.
NUVA
|
+$17.6M |
| 2 |
Amarin Corp
AMRN
|
+$14.4M |
| 3 |
Danaher
DHR
|
+$12.8M |
| 4 |
eHealth
EHTH
|
+$11.1M |
| 5 |
GSK
GSK
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AERI
Aerie Pharmaceuticals
AERI
|
+$5.19M |
| 2 |
Merck
MRK
|
+$3.53M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$3.24M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$2.67M |
| 5 |
Abbott
ABT
|
+$2.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.25% |
| 2 | Industrials | 8.36% |
| 3 | Financials | 3.65% |
| 4 | Miscellaneous | 1.46% |
| 5 | Real Estate | 0.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
PUT
Novavax
NVAX
$1.86B
| $79.9K | 0.02% |
+7,255
| New | +$229K |
2019 Q1
0 quarters
|
|
|
CNCE
52
CALL
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $27.8K | 0.01% |
+2,300
| New | +$33.9K |
2019 Q1
0 quarters
|
|
|
53
Abbott
ABT
$181B
| – | – |
-31,400
| Closed | -$2.27M | – |
|
54
Elevance Health
ELV
$92.9B
| – | – |
-2,300
| Closed | -$604K | – |
|
55
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-62,750
| Closed | -$601K | – |
|
56
Illumina
ILMN
$39.6B
| – | – |
-5,292
| Closed | -$1.54M | – |
|
57
Standard BioTools
LAB
$247M
| – | – |
-50,455
| Closed | -$435K | – |
|
|
58
Merck
MRK
$360B
| – | – |
-47,998
| Closed | -$3.53M | – |
|
59
Natera
NTRA
$56.7B
| – | – |
-39,539
| Closed | -$552K | – |
|
60
Puma Biotechnology
PBYI
$507M
| – | – |
-42,301
| Closed | -$861K | – |
|
61
Qiagen
QGEN
$9.5B
| – | – |
-52,151
| Closed | -$1.91M | – |
|
62
DELISTED
Sage Therapeutics
SAGE
| – | – |
-8,271
| Closed | -$792K | – |
|
63
CALL
Viatris
VTRS
$21.4B
| – | – |
-158,600
| Closed | -$4.35M | – |
|
|
64
Viatris
VTRS
$21.4B
| – | – |
-55,000
| Closed | -$1.51M | – |
|
|
OPNT
65
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
| – | – |
-13,901
| Closed | -$201K | – |
|
|
SPNE
66
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| – | – |
-15,459
| Closed | -$282K | – |
|
|
CFMS
67
DELISTED
Conformis, Inc. Common Stock
CFMS
| – | – |
-5,474
| Closed | -$49K | – |
|
|
EPZM
68
DELISTED
Epizyme, Inc
EPZM
| – | – |
-25,449
| Closed | -$157K | – |
|
|
BSTC
69
DELISTED
BioSpecifics Technologies Corp.
BSTC
| – | – |
-22,000
| Closed | -$1.33M | – |
|
|
GHDX
70
DELISTED
Genomic Health, Inc.
GHDX
| – | – |
-23,866
| Closed | -$1.54M | – |
|
|
LOXO
71
DELISTED
Loxo Oncology, Inc
LOXO
| – | – |
-10,000
| Closed | -$1.4M | – |
|
|
TSRO
72
DELISTED
TESARO, Inc.
TSRO
| – | – |
-36,000
| Closed | -$2.67M | – |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q1 2019 Portfolio in Review
As of Q1 2019, Eversept Partners held 72 positions worth $343M, up 86% from $185M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Eversept Partners deployed $103M of net new capital in Q1 2019, opening 18 new positions and adding to 24 existing holdings. Its largest new stake was NuVasive, Inc.: 330,601 shares worth $18.8M.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Aerie Pharmaceuticals, an estimated $5.19M trimmed.
- Eversept Partners's largest Q1 2019 buy was NuVasive, Inc.: 330,601 shares worth $18.8M.
- Eversept Partners added most to Amarin Corp in Q1 2019, an estimated $14.4M increase.
- Eversept Partners's biggest Q1 2019 reduction was Aerie Pharmaceuticals, cutting an estimated $5.19M.
- Eversept Partners fully exited Merck in Q1 2019, selling an estimated $3.53M.
- Eversept Partners's ten largest holdings make up 66% of its $343M portfolio in Q1 2019.
- Eversept Partners opened 18 new positions and closed 20 in Q1 2019.
- Eversept Partners's portfolio value rose 86% quarter-over-quarter to $343M.
Based on Eversept Partners's 13F filing for Q1 2019, filed 14 May 2019.